PMID- 31594873
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20221207
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 9
IP  - 10
DP  - 2019 Oct 7
TI  - Anti-diabetic agents for prevention of type 2 diabetes mellitus in people with 
      pre-diabetes: a systematic review and network meta-analysis protocol.
PG  - e029073
LID - 10.1136/bmjopen-2019-029073 [doi]
LID - e029073
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a substantial health problem 
      worldwide. Pre-diabetic state is associated with increased risk for the 
      development of diabetes. There are various pharmacological therapies with 
      glucose-lowering activity for diabetes prevention. Of those, most are being 
      compared with placebo instead of active agents. The relative effects and safety 
      of different glucose-lowering drugs still remain uncertain. To address this gap, 
      we will conduct a systematic review and network meta-analysis (NMA) to evaluate 
      comparative efficacy and safety of glucose-lowering agents for T2DM prevention in 
      patients with pre-diabetes. METHODS AND ANALYSIS: PubMed, the Cochrane library 
      and Embase will be searched from inception to December 2019 for relevant 
      randomised controlled trials (RCTs) that examined anti-diabetic drugs for 
      diabetes prevention in patients with pre-diabetes. Two reviewers working 
      independently will screen titles, abstracts and full papers. Data extraction will 
      also be completed by two independent authors. The primary outcome will be the 
      incidence of T2DM in patients with pre-diabetes at baseline. Secondary outcomes 
      will include the achievement of normoglycaemia, all-cause mortality, 
      cardiovascular mortality and hypoglycaemic event. Pairwise meta-analysis and NMA 
      will be conducted for each outcome using a frequentist random-effects model. 
      Additionally, subgroup analyses will also be performed. The comparison-adjusted 
      funnel plot will be used to assess publication bias. The overall quality of 
      evidence will be rated with the Grading of Recommendations Assessment, 
      Development and Evaluation framework. Data analysis will be conducted using Stata 
      V.14.0. ETHICS AND DISSEMINATION: Ethics approval is not required. We plan to 
      submit the results of this study to a peer-review journal. PROSPERO REGISTRATION 
      NUMBER: CRD42019119157.
CI  - (c) Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Xianzhe
AU  - Wang X
AD  - The Second Clinical College of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Liu, Jiabin
AU  - Liu J
AD  - The Second Clinical College of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Huang, Lijin
AU  - Huang L
AD  - The Second Clinical College of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Zeng, Hai
AU  - Zeng H
AD  - The Second Clinical College of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - He, Guoxin
AU  - He G
AD  - The First College of Guangzhou University of Chinese Medicine, Guangzhou, China.
FAU - Chen, Ling
AU  - Chen L
AD  - Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of 
      Chinese Medicine, Guangzhou, China HDNJSWLS@yeah.net zjkzh@139.com 
      HDNJSWLS1@126.com 13751714371@163.com.
FAU - Ma, Rui
AU  - Ma R
AD  - Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of 
      Chinese Medicine, Guangzhou, China HDNJSWLS@yeah.net zjkzh@139.com 
      HDNJSWLS1@126.com 13751714371@163.com.
FAU - Fu, Wenbin
AU  - Fu W
AD  - Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of 
      Chinese Medicine, Guangzhou, China HDNJSWLS@yeah.net zjkzh@139.com 
      HDNJSWLS1@126.com 13751714371@163.com.
AD  - Shenzhen Bao'an Research Center for Acupuncture and Moxibustion, Shenzhen, China.
FAU - Ning, Baile
AU  - Ning B
AD  - Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of 
      Chinese Medicine, Guangzhou, China HDNJSWLS@yeah.net zjkzh@139.com 
      HDNJSWLS1@126.com 13751714371@163.com.
AD  - Shenzhen Bao'an Research Center for Acupuncture and Moxibustion, Shenzhen, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/*prevention & control
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Network Meta-Analysis
MH  - Prediabetic State/*drug therapy
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC6797281
OTO - NOTNLM
OT  - anti-diabetic agents
OT  - diabetes
OT  - network meta-analysis
OT  - prediabetes
OT  - prevention
OT  - systematic review
COIS- Competing interests: None declared.
EDAT- 2019/10/09 06:00
MHDA- 2020/10/21 06:00
PMCR- 2019/10/07
CRDT- 2019/10/10 06:00
PHST- 2019/10/10 06:00 [entrez]
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/10/07 00:00 [pmc-release]
AID - bmjopen-2019-029073 [pii]
AID - 10.1136/bmjopen-2019-029073 [doi]
PST - epublish
SO  - BMJ Open. 2019 Oct 7;9(10):e029073. doi: 10.1136/bmjopen-2019-029073.